Hematopoietic Stem Cells (HSCs)
The treatment potential of Hematopoietic Stem Cells (HSCs) is far from exhausted. There are promising trials underway (over 1300 of them!) with these cells that have the potential to continue the revolution in treatment. Trials and tests are underway to address medical conditions such as:
- Autism
- Cerebral palsy
- Diabetes
- Multiple sclerosis (MS)
Autoimmune diseases like:
- Lupus
- Rheumatoid arthritis
- Sarcoidosis

Current USA FDA 80 Medical Conditions:
There are now over 80 medical conditions that can be treated with the Hematopoietic Stem Cells (HSCs) collected from umbilical cord blood. For the past 20+ years, Hematopoietic Stem Cell (HSC) parent consented, donor cord blood is a source for conditions such as:
- Multiple Myeloma
- Plasma Cell Leukemia
- Waldenstrom’s Macroglobulinemia
- Severe Combined Immunodeficiency (SCID)
- SCID with Adenosine Deaminase Deficiency (ADA-SCID)
- SCID which is X-linked
- SCID with absence of T & B Cells
- SCID with absence of T Cells, Normal B Cells
- Omenn Syndrome
- Lesch-Nyhan Syndrome
- Osteopetrosis
- Amegakaryocytosis / Congenital Thrombocytopenia
- Glanzmann Thrombasthenia
- Sickle Cell Disease
- Beta Thalassemia Major (Cooley’s Anemia)
- Diamond-Blackfan Anemia
- Pure Red Cell Aplasia
- Acute Leukemia
- Acute Lymphoblastic Leukemia (ALL)
- Acute Myelogenous Leukemia (AML)
- Acute Biphenotypic Leukemia
- Acute Undifferentiated Leukemia
- Chronic Myelogenous Leukemia (CML)
- Chronic Lymphocytic Leukemia (CLL)
- Juvenile Chronic Myelogenous Leukemia (JCML)
- Juvenile Myelomonocytic Leukemia (JMML)
- Adrenoleukodystrophy (ALD)
- Krabbe Disease (Globoid Cell Leukodystrophy)
- Metachromatic Leukodystrophy
- Pelizaeus-Merzbacher Disease
- Niemann-Pick Disease
- Sandhoff Disease
- Wolman Disease
- Lymphoproliferative Disorder, X-linked (Epstein-Barr Virus Susceptibility)
- Wiskott-Aldrich Syndrome
- Refractory Anemia
- Refractory Anemia with Ringed Sideroblasts (Sideroblastic Anemia)
- Refractory Anemia with Excess Blasts
- Refractory Anemia with Excess Blasts in Transformation
- Chronic Myelomonocytic Leukemia (CMML)
- Acute Myelofibrosis
- Agnogenic Myeloid Metaplasia (Myelofibrosis)
- Polycythemia Vera
- Essential Thrombocythemia
- Infantile Genetic Agranulocytosis (Kostmann Syndrome)
- Myelokathexis
- Ataxia-Telangiectasia
- Bare Lymphocyte Syndrome
- Common Variable Immunodeficiency
- DiGeorge Syndrome
- Hemophagocytic Lymphohistiocytosis
- Leukocyte Adhesion Deficiency
- Apraxia
- Chediak-Higashi Syndrome
- Chronic Granulomatous Disease
- Neutrophil Actin Deficiency
- Reticular Dysgenesis
- Neuroblastoma
- Medulloblastoma
- Cartilage-Hair Hypoplasia
- Gunther’s Disease (Erythropoietic Porphyria)
- Hermansky-Pudlak Syndrome
- Shwachman-Diamond Syndrome
- Systemic Mastocytosis
- Mucopolysaccharidoses (MPS) Storage Diseases
- Hurler’s Syndrome (MPS-IH)
- Scheie Syndrome (MPS-IS)
- Hunter Syndrome (MPS-II)
- Sanfilippo Syndrome (MPS-III)
- Morquio Syndrome (MPS-IV)
- Maroteaux-Lamy Syndrome (MPS-VI)
- Sly Syndrome (MPS-VII) (Beta-Glucuronidase Deficiency)
- Mucolipidosis II (I-cell Disease)
DISCLAIMER
AmericaOne Cell Therapy is not promising a particular outcome or making ANY claims. The USA FDA considers stem cell therapy experimental. Results vary.
Stem cell therapies have enormous promise, but the science in each use is still in the developmental stage. Professional licensed medical judgment and expertise is needed in using stem cells for any therapeutic use, and we urge anyone embarking on the use of stem cell therapies to consult the national health data bases to evaluate current information from clinical trials and the FDA websites on human tissue should also be consulted to get its current evaluation of any therapy.